The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder

BJU International

Volumn 100, Issue 1, 2007, Pages 107-110

  Dmochowski, Roger ^a   Kreder, Karl ^b   MacDiarmid, Scott ^c   Carlsson, Martin ^d   Guan, Zhonghong ^d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d PFIZER INC   (United States)

Author keywords

Bladder diaries; Efficacy; Overactive bladder; Tolterodine extended release

Indexed keywords

PLACEBO; TOLTERODINE;

ADULT; AGED; ANALYSIS OF COVARIANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL DOCUMENTATION; MICTURITION; OVERACTIVE BLADDER; PATIENT COMPLIANCE; POST HOC ANALYSIS; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; URINE VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BENZHYDRYL COMPOUNDS; CRESOLS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE; URODYNAMICS;

EID: 34249937883     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06926.x     Document Type: Article

References (12)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society. Urology 2003 61 : 37 49
2. van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001 57 : 414 21
3. Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002 41 : 588 95
4. Siami P, Seidman LS, Lama D. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clin Ther 2002 24 : 616 28
5. Garely AD, Burrows L. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults. Drug Saf 2004 27 : 1043 57
6. Olsson B, Szamosi J. Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder. Clin Pharmacokinet 2001 40 : 135 43
7. Olsson B, Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet 2001 40 : 227 35
8. Staskin DR, Wein A. Is it possible to make cross-study comparisons of urinary continence rates in patients with overactive bladder? Curr Med Res Opin 2005 21 : 835 7
9. Jennum P. Sleep and nocturia. BJU Int 2002 90 (Suppl. 3 21 4
10. Schick E, Jolivet-Tremblay M, Dupont C, Bertrand PE, Tessier J. Frequency-volume chart: the minimum number of days required to obtain reliable results. Neurourol Urodyn 2003 22 : 92 6
11. Wyman JF, Choi SC, Harkins SW, Wilson MS, Fantl JA. The urinary diary in evaluation of incontinent women: a test-retest analysis. Obstet Gynecol 1988 71 : 812 7
12. Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z on behalf of the 037 Study Group. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006 67 : 731 6